Connect with us

SPAC Insiders

Top 3 SPAC Targets: Biotech Firms in Neurology

Published

on

SPACInsider contributor Anthony Sozzi this week compiled his three favorite potential SPAC targets in neurology biotech. We look at why they are compelling and why each could be a fit for a blank-check merger.


As we found in our 1H-2021 Report, Biotech accounted for the third-most announced and completed deals in the first half of 2021, but the clearest reason why now is a good time to dive deeper into biotech is more specific. Chamath Palihapitiya appears poised to energize SPAC involvement in the sector with four new vehicles listed as a result of his joint venture between Social Capital and Survetta Holdings. And, where Palihapitiya treads, other SPAC teams are sure to follow.

In the coming weeks, we are going to take a look at each of the Social Capital Survetta SPACs and the fields of medicine that they are focused on in a somewhat different format. But, for now, we’re going to look at the neurology space specifically and three companies that his team and others should have on their radars.

Survetta is an investment firm founded in 2011 with over $4.5 billion is assets that focuses on long-term investment horizons. In 2020, Survetta launched its Averill fund as a separate healthcare-oriented investment vehicle focusing on disrupting the current methods of managing or treating diseases that have thus far been a mystery to cure. With Averill posting 200% gains in its first year, it should not come as a shock that Palihapitiya and Survetta caught each other’s attention.

Social Capital Survetta I (NASDAQ:DNAA), the first of the partnership’s four biotech-focused SPACs, is concentrating on neurology. More specifically, the management team is seeking to capitalize on advancements in nervous system therapeutics, such as novel platforms to help manage and treat brain and nervous system disorders, which includes neurological and psychiatric diseases and pain management.

This is a fairly broad area of drug development that is expected to grow precipitously as the US population ages. As many as 55% of people aged 55 or older are diagnosed with at least one neurological disorder and Alzheimer’s dementia alone afflicts about 1 in 10 people over 65. As such, the market for neurological disorder drugs is expected to grow at a CAGR of 5% through 2027 to $112 billion.

Another unique card that DNAA has to play is its Director Vladimir Coric, who serves as the CEO of Biohaven Pharmaceuticals (NYSE:BHVN), a commercial-stage company focused on treating disorders of the central nervous system (CNS).

Coric has conducted clinical trials for candidates to treat various CNS disorders, including obsessive compulsive disorder, generalized anxiety disorder, major depression, schizophrenia, schizoaffective disorder, migraines, Alzheimer’s, hepatocellular carcinoma and glioblastoma.

That’s a long list, but it provides some dots to connect to the field of biotech companies advancing drug candidates in this space.


Neurotrack

Silicon Valley-based Neurotrack hosts a suite of cognitive assessments that leverage eye-tracking technology to monitor early warning signs of cognitive decline or Alzheimer’s. These digital assessments track processing speed, recognition memory, associative learning and memory, inhibition, attention and executive function.

This puts it into an interesting gap in the treatment timeline for Alzheimer’s. It is not yet an FDA-approved as a diagnostic tool for Alzheimer’s, but, in many cases, it is monitoring patients so early on that Alzheimer’s would not be diagnosable in the first place. Instead, it is currently in use as a largely tool to pick up early warning signs when interventions in diet and activity change might stave off symptoms detected by its tools.

Alzeimer’s is currently an incurable disease with 146 of 150 drug candidates over the past two decades failing to demonstrate treatment efficacy in clinical trials. As such, Neurotrack’s approach helps reduce the risk early and reduce the effects in the future. It has completed Phase I trials as it works towards a clinical debut and secured funding for Phase II in 2019.

To date, Neurotrack has raised a total of $47.56M with Social Capital investing in both the Series A and B for a total of $25.56 million. Social Capital is not the only SPAC-connected investor on its cap table, however, as its $21 million Series C was led by Khosla Ventures, which is backing one SPAC in the searching column – Khosla Ventures III (NASDAQ:KVSC) – and has filed to IPO another.

Pipeline Therapeutics

Pipeline Therapeutics is a developer of regenerative therapies designed to promote functional recovery of neurological diseases to repair different nervous system cell types to treat diseases such as multiple sclerosis (MS). The other therapies that the company is developing include treating sensorineural hearing loss by advancing therapeutics to initiate synaptic reconnection and repairing axons to restore function in neurological disorders.

In its latest VC funding round, the company raised $80M, which included a cash payment from the Survetta Capital Management’s Averill Master Fund.

Currently, the San Diego-based company is in Phase I clinical trials for its’ PIPE-307 MS program, which is set to complete in July 2021. In addition to their MS therapy, PIPE-505 which is targeting synapse and hearing regeneration, is in Phase 2 of development and will be assessed at one, two and three months following the injections.

AZTherapies

AZTherapies is a clinical-stage biopharmaceutical company that aims to change the progression of neurodegenerative diseases, extending normal cognition and function and improving quality of life for aging patients.

Currently, their pipeline of therapeutics is centered around ALZT-OP1, which, in different forms is being tested as a potential treatment for Alzheimer’s, ALS and ischemic stroke. It has already passed or is now entering Phase II clinical trials for each of these treatment cases. In their preclinical discoveries, the team is developing a chimeric antigen receptor (CAR) to direct regulatory T cells to the CNS to restore a health balance of cells in the brain.

Since 2015, AZTherapies has raised $115.3 million from biotech investors, which, has been used to progress to Phase 3 trials for its first-in-class candidate to slow the progression of Alzheimer’s disease. The trial is now complete with top-line data expected to be ready by the end of this year.

Phase III is the final step before a drug developer can formally file for an application to approve a treatment for marketing. These final steps can still take some time, but ALZT-OP1 is nonetheless close to becoming just the fifth approved Alzheimer’s treatment over the past 20 years.

PlatoAi. Web3 Reimagined. Data Intelligence Amplified.
Click here to access.

Source: https://spacinsider.com/2021/07/09/top-3-spac-targets-biotech-firms-in-neurology/

SPAC Insiders

Software Acquisition Group Inc. II (SWAGU) Prices $200M IPO

Published

on

IPO-Pricing

Jul 28, 2021 IPOs by Marlena Haddad

Software Acquisition Group Inc. II announced the pricing of its $200 million IPO and its shares are expected to begin trading on the Nasdaq under the symbol “SWAGU” Thursday, July 29.

The new SPAC aims to combine with a software target that has an enterprise value of $600 million or more along with compelling growth prospects. Software Acquisition Group II is led by Chairman, CEO, and CFO Jonathan S. Huberman along with VP of Acquisitions Mike Nikzad.

Total SPAC deal count for 2021 year-to-date is now 386. This offering is expected to close on Monday, August 2.


Jefferies is serving as the sole book-running managers for the offering. Kirkland & Ellis LLP is serving as Issuer’s Counsel with Paul Hastings LLP serving as Underwriter’s Counsel. Marcum LLP serves as auditor. Continental Stock Transfer & Trust Company is acting as trustee.

PlatoAi. Web3 Reimagined. Data Intelligence Amplified.
Click here to access.

Source: https://spacinsider.com/2021/07/28/software-acquisition-group-inc-ii-prices-200m-ipo/

Continue Reading

SPAC Insiders

Software Acquisition Group Inc. II (SWAGU) Prices $200M IPO

Published

on

IPO-Pricing

Jul 28, 2021 IPOs by Marlena Haddad

Software Acquisition Group Inc. II announced the pricing of its $200 million IPO and its shares are expected to begin trading on the Nasdaq under the symbol “SWAGU” Thursday, July 29.

The new SPAC aims to combine with a software target that has an enterprise value of $600 million or more along with compelling growth prospects. Software Acquisition Group II is led by Chairman, CEO, and CFO Jonathan S. Huberman along with VP of Acquisitions Mike Nikzad.

Total SPAC deal count for 2021 year-to-date is now 386. This offering is expected to close on Monday, August 2.


Jefferies is serving as the sole book-running managers for the offering. Kirkland & Ellis LLP is serving as Issuer’s Counsel with Paul Hastings LLP serving as Underwriter’s Counsel. Marcum LLP serves as auditor. Continental Stock Transfer & Trust Company is acting as trustee.

PlatoAi. Web3 Reimagined. Data Intelligence Amplified.
Click here to access.

Source: https://spacinsider.com/2021/07/28/software-acquisition-group-inc-ii-prices-200m-ipo/

Continue Reading

SPAC Insiders

Starboard Value Acquisition Corp. (SVAC) Shareholders Approve Cyxtera Deal

Published

on

Continue Reading

SPAC Insiders

Starboard Value Acquisition Corp. (SVAC) Shareholders Approve Cyxtera Deal

Published

on

Continue Reading
AR/VR3 days ago

Review: Winds & Leaves

Esports5 days ago

Legends of Runeterra adding new Lab of Legends mode: The Saltwater Scourge

IOT5 days ago

The Current State of Indoor Positioning with IoT | Navigine’s Alexey Panyov and Elvina Sharafutdinova

Cleantech5 days ago

The Grim Reaper & The Republican Party Embracing Climate Action Are The Only Things That Will Eliminate US Climate Change Deniers

Esports4 days ago

New World Faction Armor Sets

Esports4 days ago

Are Splitgate’s servers down? Here’s how to check server status

Esports5 days ago

Best Build for Lucario in Pokemon UNITE

Esports5 days ago

How to level up every trade skill in New World

Esports5 days ago

Valorant PBE Server Status: How to Check

Blockchain4 days ago

DigiMax Expands Global Marketing into Asia with Signing of Collaboration Deal in Hong Kong

Esports5 days ago

Twitch and Facebook Gaming set new records, YouTube Gaming sees viewership decrease in Q2 2021

Energy5 days ago

Innovation at the Interconnection Solves Inrush Current Issue on PV Solar+Storage Site in NC

Esports5 days ago

Broken Blade talks about Schalke 04’s disappointing 2021 Summer Split, his responsibility as one of the older players on the roster

Esports5 days ago

TSM and Gen.G VALORANT meet again in NA VCT Stage 3 Challengers 2 opener

Esports5 days ago

LCO caster Rusty condemns Chiefs Esports Club for ‘disrespectful’ behavior in week 7 win over Mammoth

SPAC Insiders4 days ago

Mercury Ecommerce Acquisition Corp. (MEACU) Prices $175M IPO

Blockchain5 days ago

European Digital Identity: Talao Announces Professional Credential Solution

Energy5 days ago

Duke Energy helps build North Carolina workforce with $615,000 in grants to community colleges, HBCUs and nonprofits

Esports4 days ago

How Many People Can Play Tribes of Midgard Together?

AR/VR5 days ago

Oculus Quest 2 Sales Paused Until Late August Due to Facial Interface, Silicone Cover Incoming

Trending